[{"address1": "Wagistrasse 25", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 733 4747", "fax": "41 44 733 4740", "website": "https://www.kuros.ch", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 80, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christopher T. Fair", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 521200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Geiger", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sjoerd  Musters", "age": 43, "title": "COO & GM of BV", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.", "age": 57, "title": "President of Innovation and Strategy & Executive Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 572600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. G. Joseph Ross", "age": 55, "title": "Senior Vice President of Marketing & Business Development", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nikki  Coleman", "title": "Vice President of Global Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philippe  Saudan Ph.D.", "age": 56, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Griffin", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Katherine  Sage D.O., FAAOS, M.S.", "title": "Senior Vice President of Medical & Clinical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Virginia  Jamieson", "age": 70, "title": "Consultant", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.14, "open": 12.2, "dayLow": 12.2, "dayHigh": 12.76, "regularMarketPreviousClose": 12.14, "regularMarketOpen": 12.2, "regularMarketDayLow": 12.2, "regularMarketDayHigh": 12.76, "beta": 1.0, "volume": 109041, "regularMarketVolume": 109041, "averageVolume": 240437, "averageVolume10days": 222891, "averageDailyVolume10Day": 222891, "bid": 12.74, "ask": 12.78, "marketCap": 468693504, "fiftyTwoWeekLow": 1.755, "fiftyTwoWeekHigh": 13.36, "priceToSalesTrailing12Months": 8.920359, "fiftyDayAverage": 11.9554, "twoHundredDayAverage": 7.0248, "currency": "CHF", "enterpriseValue": 243840992, "profitMargins": -0.16912001, "floatShares": 14171393, "sharesOutstanding": 36905000, "heldPercentInsiders": 0.3481, "heldPercentInstitutions": 0.09924, "impliedSharesOutstanding": 37026600, "bookValue": 2.852, "priceToBook": 4.4530153, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -8886000, "trailingEps": -0.38, "lastSplitFactor": "1:100", "lastSplitDate": 1466640000, "enterpriseToRevenue": 4.641, "enterpriseToEbitda": -79.948, "52WeekChange": 5.1313133, "SandP52WeekChange": 0.2338835, "exchange": "EBS", "quoteType": "EQUITY", "symbol": "KURN.SW", "underlyingSymbol": "KURN.SW", "shortName": "Kuros N", "longName": "Kuros Biosciences AG", "firstTradeDateEpochUtc": 1035878400, "timeZoneFullName": "Europe/Zurich", "timeZoneShortName": "CEST", "uuid": "5a3030ec-7ed6-331a-a734-dbdb1ca2d062", "messageBoardId": "finmb_4422885", "gmtOffSetMilliseconds": 7200000, "currentPrice": 12.7, "recommendationKey": "none", "totalCash": 14277000, "totalCashPerShare": 0.677, "ebitda": -3050000, "totalDebt": 1964000, "quickRatio": 2.076, "currentRatio": 2.733, "totalRevenue": 52542000, "debtToEquity": 3.264, "revenuePerShare": 1.806, "returnOnAssets": -0.03766, "returnOnEquity": -0.14317, "freeCashflow": -6043375, "operatingCashflow": -2415000, "revenueGrowth": 1.475, "grossMargins": 0.87766, "ebitdaMargins": -0.05805, "operatingMargins": -0.017549999, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-08-14"}]